Quick Answer
Kymera Therapeutics, Inc. reported R&D Expense of $316.57 million for fiscal year 2025.
Kymera Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $316.57M | +31.8% |
| 2024 | $240.25M | +27.1% |
| 2023 | $189.08M | +15.1% |
| 2022 | $164.25M | +19.9% |
| 2021 | $137.02M | +120.6% |
| 2020 | $62.10M | +67.1% |
| 2019 | $37.16M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $74.09M | +22.7% | -5.5% |
| June 30, 2025 | $78.39M | +32.4% | -2.3% |
| March 31, 2025 | $80.25M | +64.4% | +32.9% |
| September 30, 2024 | $60.41M | +25.5% | +2.0% |
| June 30, 2024 | $59.20M | +29.4% | +21.3% |
| March 31, 2024 | $48.82M | +15.6% | +1.5% |
| September 30, 2023 | $48.12M | +9.7% | +5.1% |
| June 30, 2023 | $45.77M | +10.8% | +8.4% |
- Kymera Therapeutics, Inc. showed an increase of +31.8% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Kymera Therapeutics, Inc.’s r&d expense has grown by 752.0% (from $37.16 million to $316.57 million).
- The most recent figure is from Kymera Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: